Status: Not yet recruiting
Low-dose Colchicine for Thromboprophylaxis After Transcatheter Aortic Valve Replacement
This prospective, randomized, open-label study aims to evaluate the efficacy and safety of low-dose colchicine (0.5 mg daily) in reducing transcatheter heart valve (THV) thrombosis in patients after TAVR. Participants will be randomly assigned to either receive colchicine plus standard care or standard care alone for 12 months. The primary goal is to compare the rate of valve thrombosis between the two groups using 4D-CT imaging at one year. Additionally, the study will evaluate the treatment's impact on clinical outcomes and its overall safety profile.
Participants needed: 116
Trial details
Age: 60-85Biological sex: AllType: InterventionalSponsor: China National Center for Cardiovascular DiseasesUpdated: Mar 12, 2026Locations: 1
Eligibility criteria
Patients with aortic stenosis aged 60-85 years. [+2]
Known hypersensitivity, allergy, or documented intolerance to colchicine. [+13]